All In Biotech

Drug Trial Radar · NCT06411301

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 2024

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Jules Bordet InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
RayzeBio, Inc.
First posted
May 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to determine the safety and the recommended phase II dose of RYZ101 (actinium-225 labelled DOTA-octreotate (225Ac-DOTATATE)) in participants with refractory and relapsing multiple myeloma (MM) that have received at least 3 prior lines of myeloma therapy. Participants will be selected based on somatostatin receptor (SSTR) positivity assessed by gallium-68 labelled DOTA-octreotate (68Ga-DOTATATE) PET/CT. The response to 225Ac-DOTATATE therapy will also be assessed in the target study population.

Conditions

  • Multiple Myeloma, Refractory
  • Multiple Myeloma in Relapse
  • Multiple Myeloma Progression

Interventions

  • 225Ac-DOTATATEDrug

    Two intravenous infusions every 6 weeks (Q6W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of 225Ac-DOTATATETime frame: First 84 days following first 225Ac-DOTATATE injection
  2. Recommended phase II dose of 225Ac-DOTATATETime frame: First 84 days following first 225Ac-DOTATATE injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jules Bordet Institute

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.